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Many viruses express proteins which prevent the host cell death that their infection would otherwise provoke. Some insect
viruses suppress host apoptosis through the expression of caspase inhibitors belonging to the P35 superfamily. Although a
number of P35 relatives have been identiﬁed, Autographa californica (Ac) P35 and Spodoptera littoralis (Spli) P49 have been the
most extensively characterized. AcP35 was found to inhibit caspases via a suicide substrate mechanism: the caspase cleaves
AcP35 within its ‘reactive site loop’ then becomes trapped, irreversibly bound to the cleaved inhibitor. The Maruca vitrata
multiple nucleopolyhedrovirus encodes a P35 family member (MaviP35) that exhibits 81% identity to AcP35. We found that this
relative sharedwith AcP35 the abilityto inhibit mammalian andinsectcell death. Caspase-mediatedcleavagewithinthe MaviP35
reactive site loop occurred at a sequence distinct from that in AcP35, and the inhibitory proﬁles of the two P35 relatives differed.
MaviP35 potently inhibited human caspases 2 and 3, DCP-1, DRICE and CED-3 in vitro, but (in contrast to AcP35)
only weakly suppressed the proteolytic activity of the initiator human caspases 8, 9 and 10. Although MaviP35 inhibited the
AcP35-resistant caspase DRONC in yeast, and was sensitive to cleavage by DRONC in vitro, MaviP35 failed to inhibit the
proteolytic activity of bacterially produced DRONC in vitro.
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Cell death is essential for normal animal development and to
destroypre-cancerousand auto-immune cells,but it hasbeen
postulated that apoptosis originally evolved to defend
primitive multicellular organisms against intracellular patho-
gens such as viruses.
1 Over evolutionary time, an ‘arms race’
has developed between viruses and their hosts. Cellular
machineries detect infection and activate self-destruction
pathways, limiting the ability of the virus to replicate and
spread to other cells. Viruses, in turn, have evolved ways to
suppress their hosts’ apoptotic machineries during the early
phase of infection. Targeting caspases is one approach
adoptedbyviruses toblock their host cells’suicidal reactionto
infection.
2 The P35 family is a group of caspase inhibitors
encoded by viruses that infect insects. Almost all of the
viruses that possess P35 relatives are baculoviruses:
3 the
sole exception known to date is the Amsacta moorei
entomopoxvirus.
4 No cellular P35 homologs have been
described as yet, although as baculoviruses usually derive
their genes from their hosts,
5 it seems likely that P35 genes
did evolve from a cellular ancestor.
The best-studied P35 family member is AcP35, encoded by
the baculovirus Autographa californica multi nucleopolyhe-
drovirus (AcMNPV).
6 It inhibits caspases via a substrate trap
mechanism.
7–9 The caspase cleaves AcP35 within the
reactive site loop. This cleavage provokes a conformational
change within the inhibitor, targeting its amino terminus to the
caspase’s active site, preventing hydrolysis of a thioester
adduct between the inhibitor and the protease, and
thus locking the caspase in an inactive, P35-bound form.
7
Of the many mammalian, insect and nematode caspases
tested, very few were found to be insensitive to AcP35.
The Drosophila initiator caspase DRONC was shown to be
resistant to inhibition by AcP35.
10,11 Processing of down-
stream Spodoptera caspases proceeded in the presence of
AcP35,
12 implying that a Spodoptera DRONC ortholog
(denoted ‘Sf-caspase-X’) is also resistant to AcP35 inhibition.
AcP35 could inhibit the enzymatic activity of recombinant
caspase 9 (DRONC’s mammalian counterpart), however
extremely high concentrations of AcP35 were required to
prevent apoptosome-activated caspase 9 from cleaving its
physiological substrate, caspase 3.
13 This suggests that
AcP35 cannot efﬁciently interfere with the function of naturally
activated caspase 9.
Bombyx mori nucleopolyhedrovirus (BmNPV) encodes a
protein (BmP35), which shares 91% of its amino-acid
sequence with AcP35. BmP35 displayed only weak
anti-apoptotic activity
14 and, unlike AcP35, BmP35 was
dispensable for normal viral propagation.
15,16 Extracts from
mammalian cells expressing BmP35 were less potent than
lysates from AcP35-expressing cells at inhibiting recombinant
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have contributed to this difference.
13 No quantitative data
havebeenpublishedregardingthecaspaseinhibitorypotency
or speciﬁcity of BmP35, and no other close relatives of AcP35
have been functionally or biochemically investigated to date.
Some baculoviruses encode distant relatives of AcP35,
whichconstitutetheP49subfamily.Spodopteralittoralis (Spli)
NPV-P49 is the best-studied member of this subfamily.
Like AcP35, SpliP49 is a broad-spectrum caspase inhibitor
that could suppress insect
17–20 and mammalian
21 cell death.
Unlike AcP35, SpliP49 could inhibit DRONC-mediated yeast
lethality,
21 but it was incapable of preventing DRICE proces-
sing in Drosophila cells.
19 SpliP49 could, however, prevent
processing of executioner Spodoptera caspases,
18,20 imply-
ing that it can inhibit the proposed Sf-caspase-X. AcP35
contains the cleavage sequence DQMD’G within its reactive
site loop, but SpliP49 instead possesses the sequence
TVTD’G at this position. This sequence is required for
SpliP49 to inhibit the distal insect caspase Sf-caspase-X,
but its insertion into the AcP35 reactive site loop failed to
confer this capability,
20 indicating that other regions of the
SpliP49 protein, not shared by AcP35, are critical for its ability
to inhibit insect initiator caspases. The caspase inhibitor
AMVP33 from Amsacta moorei entomopoxvirus is the least
homologous member of the P35 superfamily, exhibiting only
25% amino acid identity to AcP35.
4
The baculovirus Maruca vitrata (Mavi) MNPV infects
the legume pod borer Maruca vitrata, and may offer a
biological means of controlling this important pest of legume
crops.
22 The recent sequencing of the MaviMNPV genome
23
revealed the presence of a P35 ortholog (MaviP35). The
predictedMaviP35proteinishighlyhomologoustoAcP35,but
its predicted reactive site loop possesses a distinct caspase
cleavage sequence. Here, we report our characterization of
the apoptosis and caspase inhibitory properties of MaviP35.
Results
Sequencing of the MaviMNPV genome
23 revealed that this
virus encoded a P35 ortholog that was 81% identical to the
founding member of this family, AcP35 (Figures 1a and b),
and modeling suggested the two relatives may adopt similar
structures (Figures 1c and d). Residues determined to be
essential for the caspase inhibitory activities of AcP35,
including C2
8 and D87,
24,25 were conserved in MaviP35,
suggesting it too may function as a caspase inhibitor that
could prevent apoptosis. We tested this hypothesis by
overexpressing MaviP35 in mammalian and insect cells,
and monitoring the transfectants’ sensitivity to apoptosis.
MaviP35 inhibited insect cell death and caspase activity
triggered by infection with an AcP35-deﬁcient baculovirus,
although less efﬁciently than AcP35 (Figures 2a and b).
MaviP35 and AcP35 inhibited insect cell death induced by
actinomycin D to a similar extent (Figure 2c), but MaviP35
protected a larger proportion of insect cells than AcP35
against apoptosis induced by UV irradiation (Figure 2d).
MaviP35 and AcP35 afforded similar levels of protection to
mammalian cells against cisplatin-induced apoptosis
(Figure 2e), but MaviP35 was less protective than AcP35
against death induced by TNF-related apoptosis-inducing
ligand (TRAIL; Figure 2f).
We have previously exploited yeast-based assays to
visualize caspase activity and inhibition, and these were used
to provide an indication of the speciﬁcity of MaviP35 for
various caspases. MaviP35 protected yeast from death
induced by mammalian caspases 1, 2, 3, 5, 7 and 8, the
Drosophila caspases DCP-1 and DRICE, and CED-3 from
Caenorhabditis elegans (Figure 3). In this system, MaviP35
appeared to exhibit similar activity to AcP35, and protected
yeast from death induced by caspases 5, 8 and CED-3 better
than SpliP49 (Figure 3).
AcP35 has been shown to inhibit caspases via a pseudo-
substrate mechanism, and mutation of the caspase cleavage
site abolishes caspase and apoptosis inhibitory activity.
7,8
Comparison of the MaviP35 and AcP35 sequences predicted
that caspases may cleave MaviP35 after residue D
87 within
the site TQFD
870
G (Figure 1a). Consistent with this residue
beingcriticalforcaspaseinhibition,aputativeP1mutantfailed
to prevent DRICE induced yeast death (Figure 4). Lysates
from yeast expressing active DRICE exhibited considerable
DEVDase activity. Co-expression of untagged or carboxyl
terminally FLAG-tagged wild-type MaviP35 or AcP35 abol-
ished this activity, but their cleavage site mutants had
negligible impact (Figure 4). Immunoblotting conﬁrmed that
the tagged mutants were expressed at least as abundantly as
their wild-type counterparts. Interestingly, cleavage products
could not be detected in lysates from yeast co-expressing
DRICE with either MaviP35-FLAG or AcP35-FLAG. Because
DRICE activity in this system is generated through auto-
activation, we suspect that only relatively few P35 molecules
would be required to block this feedback loop, and immuno-
blotting may not be sufﬁciently sensitive to detect this small
number of cleaved proteins.
The yeast system is a sensitive tool for observing caspase
inhibition within a naive eukaryotic environment, but only
provideslimitedinsightintothestrengthofinhibition.Togaina
quantitative understanding of MaviP35’s caspase inhibitory
activity, we puriﬁed FLAG-tagged MaviP35 and AcP35 and
examined their ability to prevent recombinant caspases from
cleaving ﬂuorogenic substrates in vitro. When present at 100–
1000-fold excess, MaviP35 diminished by at least 90% the
activity of caspases 2, 3, DRICE, DCP-1 and CED-3. Weaker
inhibition was seen for caspases 1 and 7. MaviP35 only
partially reduced the activity of caspases 6, 8 and 9, and
negligible inhibition of caspase 10 was observed (Figure 5). A
particularly striking difference between AcP35 and MaviP35
related to inhibition of caspase 8. As observed previously,
26
AcP35 potently suppressed the proteolytic activity of this
enzyme, yet a 100-fold excess of MaviP35 only decreased its
activity by about half (Figure 5).
The alignment of P35 subfamily members revealed that the
P4 and P2 residues differed between AcP35 and MaviP35
(P4-DQMD-P1 versus P4-TQFD-P1, respectively). Muta-
genesis studies of AcP35 had previously demonstrated that
changing its P4 aspartate residue to either alanine or
asparagine markedly impaired its ability to inhibit caspases
3 and 8,
7 highlighting the importance of the P4 amino acid for
caspaseinhibition.ThecleavagesiteofMaviP35,containinga
P4 threonine residue, was reminiscent of the site at which
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Cell Death and DiseaseDRONC auto-processes between its large and small subunit
(TQTE)
11 and, to a lesser extent, the caspase cleavage site
within the SpliP49 reactive site loop (TVTD).
17 This prompted
us to wonder whether MaviP35 may be the ﬁrst example of a
P35 subfamily member that can inhibit DRONC. Consistent
with this notion, expression of MaviP35 completely abolished
DRONC-mediated yeast death (Figure 6a) and recombinant
DRONC could cleave puriﬁed MaviP35, although not as
Figure1 RelationshipsbetweenMaviP35andtheotherP35subfamilymembers.(a)AlignmentofbaculoviralP35subfamilyproteins.Colorintensityreﬂectsthedegreeof
conservation within thefamily.A pink box showsthe P4-P10 region(based on AcP35)andthe caspasecleavagesiteis marked byan arrow.(b) Anaveragedistancetree was
calculated using percentage identity from the multiple sequence alignment. The AcP35 structure (c) and predicted structure of MaviP35 (d) are shown. The positions of the
AcP35 P1 aspartate residue and the corresponding residue in MaviP35 are indicated by arrows
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to determine whether MaviP35 could suppress DRONC
activity in insect cells. DRONC can cleave DRICE between
its large and small subunits
10,11 and cleavage of DRICE in
Drosophila cells has previously been used as a readout
of DRONC activity.
19,27 A GFP-tagged active site mutant of
DRICE expressed in Drosophila Kc167 cells was completely
processed to yield a 39-kDa product following actinomycin D
treatment (Figure 6d), as expected from DRONC cleavage
between the large and small subunits of DRICE (Figure 6e).
Enforced expression of DIAP1 completely inhibited cleavage
of DRICE
C211A-eGFP in actinomycin D-treated Drosophila
cells (Figure 6). Curiously, AcP35 partially inhibited
DRICE
C211A-eGFP cleavage, with more than half of the
protein remaining intact in cells co-expressing AcP35.
MaviP35 also partially inhibited this cleavage event, although
Figure 2 MaviP35 inhibits mammalian and insect cell death. (a, b) Sf9 cells
were transfected with plasmids encoding MaviP35-FLAG, AcP35-FLAG or
chloramphenicol acetyl transferase (CAT), then infected with an AcP35-mutant
baculovirus. Untransfected cells were subjected to mock infection. (a) Survival was
monitoredrelativeto themock-infected cells. (b)Caspaseactivity was detectedand
expressed relative to the DEVDase activity in infected cells expressing the negative
control CAT protein. (c and d) Sf21 cells were co-transfected with plasmids
encoding GFP and the speciﬁed proteins. After 4h heat shock-mediated induction
of transgene expression, the cells were treated with actinomycin D (c)o rU V( d).
Viability is expressed as the number of GFP-positive cells following exposure to
apoptotic stimuli, relative to their number before treatment. (e and f) MEF (e)o r
LN18 glioblastoma cells (f) were co-transfected with a b-galatosidase expression
plasmid and either an empty vector (solid lines), or plasmids encoding MaviP35
(dashed lines) or AcP35 (dotted lines), before treatment with the indicated doses of
either cisplatin (e) or crosslinked TRAIL (f). Following 5-bromo-4-chloro-3-indolyl-b-
D-galactopyranoside staining, the survival of blue (transfected) cells was scored
using morphological criteria. Over 80 (e) or 150 (f) blue cells were scored for each
condition per experiment. Error bars represent S.E.M. from three separate
experiments (a–f)
Figure 3 MaviP35 inhibits caspase-dependent yeast death. Yeast were
transformed with the indicated expression plasmids. Suspensions containing
equivalentconcentrationsofeachtransformantwereseriallydilutedand5mlofeach
dilution were spotted onto plates containing galactose (to induce transgene
expression) or glucose (to repress transgene expression). Growth on inducing
plates indicates survival and proliferation of yeast expressing the transgenes
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ability of recombinant DRONC to cleave a peptide substrate
(Figure 6f). Using a range of substrate and inhibitor
concentrations, inhibition by bacterially produced DRONC
of MaviP35 was extremely weak (Figure 7). Quantitation
of MaviP35’s inhibition of other caspases conﬁrmed the
data shown in Figure 5: strong inhibition of executioner
caspases, but weak to negligible inhibition of initiator
caspases (Figure 7c).
Discussion
This study describes the apoptosis and caspase inhibitory
properties of a new P35 subfamily member: MaviP35. Like
AcP35, MaviP35 could inhibit insect and mammalian cell
death, was susceptible to caspase cleavage, and could inhibit
the proteolytic activity of caspases. Nevertheless, AcP35 and
MaviP35 differed in their speciﬁcity proﬁle. MaviP35 inhibited
executioner apoptotic caspases with similar potency to
AcP35. However, MaviP35 was substantially less potent than
AcP35 at inhibiting mammalian caspases 8 and 10. This may
explain the weaker protection afforded by MaviP35 relative to
AcP35 against TRAIL-induced cell death. MaviP35was also a
weaker inhibitor of recombinant caspase 9 than AcP35.
However, it is important to note that published data suggest
that the susceptibility of recombinant caspase 9 to AcP35 in
vitro is not mirrored by apoptosome-activated caspase 9
within cell lysates,
13 so it is possible that AcP35 and MaviP35
are both incapable of interfering with the activity of naturally
activated caspase 9 in vivo.
The P4 residue of MaviP35 (threonine) differs from that of
AcP35 (aspartate). Mutation of P4 in AcP35 to asparagine
reduceditsabilitytoinhibitcaspase3by47-fold,
7yetMaviP35
– which contains the slightly larger polar uncharged residue
threonine at this position – inhibited caspase 3 with similar
efﬁciencytowild-typeAcP35.Presumablydifferencesinother
regions of the protein compensate, allowing MaviP35 to
efﬁcientlysuppresscaspase3activity.TheMaviP35cleavage
siteresemblestheauto-processingsitebetweenthelargeand
small subunits of DRONC, and MaviP35 was sensitive to
DRONC proteolysis in vitro. MaviP35 inhibited yeast death
triggered byhigh-levelexpressionofDRONC, suggestingthat
it could function as a pseudo-substrate inhibitor of DRONC.
However, two pieces of evidence argue against this possibi-
lity. First, MaviP35 was an extremely weak inhibitor of
recombinant DRONC activity in vitro. Its Ki was indistinguish-
able from that of AcP35, which was incapable of inhibiting
DRONC in yeast and in vivo
10,11 and was resistant to DRONC
cleavage in vitro. Second, MaviP35 only partially inhibited
actinomycin D-induced cleavage of the DRICE
C211A–eGFP
fusion protein, impeding processing to a lesser extent than
AcP35. This result implies that actinomycin D treatment
provoked DRONC-mediated (AcP35/MaviP35 resistant) pro-
cessing of the DRICE-eGFP substrate in Kc167 cells, but also
suggested that other proteases, sensitive to AcP35/MaviP35
inhibition, also contributed to this proteolysis. Taken together,
these data lead us to postulate that MaviP35 functions as a
classical substrate for DRONC, rather than as a suicide
substrate inhibitor. It is possible that the ability of MaviP35 to
suppress DRONC-mediated yeast lethality reﬂects substrate
competition: DRONC’s proteolytic attention may be diverted
toMaviP35processingratherthancleavageofessentialyeast
proteins.
Despite the high homology between MaviP35 and AcP35,
thisstudyhasrevealedanimportantdifferenceintheircaspase
speciﬁcity. Both inhibitors could suppress downstream cas-
pasesfrominsectsandmammals(andCED-3),butonlyAcP35
could efﬁciently block the activities of mammalian caspases-8
and -10. Neither AcP35 nor MaviP35 could signiﬁcantly inhibit
the Drosophila initiator caspase DRONC.
Figure4 MaviP35activityrequirestheP1aspartateresiduebutisunaffectedby
addition of a C-terminal FLAG tag. Yeast were transformed with the indicated
expression plasmids. Suspensions containing equivalent concentrations of each
transformant were serially diluted, and 5ml of each dilution were spotted onto
inducing and repressing plates. The caspase activities of induced transformants’
lysates were compared using the ﬂuorogenic Ac-DEVD-AFC substrate. Anti-FLAG
immunoblotting was performed and loading was visualized by coomassie staining
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Sequence comparisons and structural modeling. Sequences of
the P35 subfamily members were aligned using the ‘Multialign’ program
28 and
formatted using Jalview 2.0.
29 Genbank accession numbers for the P35 sequences
used were: MaviMNPV: YP_950833, AcMNPV: NP_054165.1, RoMNPV:
NP_703122, BmNPV: AAO12972, HycuNPV: AAO17287, SpltNPV: CAA71304
and LeseNPV: AAF78504. Protein Homology/analogY Recognition Engine (Phyre)
was used to predict the structure of MaviP35.
30 AcP35 and predicted MaviP35
structures were depicted using Jmol: an open-source Java viewer for chemical
structures in 3D (http://www.jmol.org/).
Plasmid construction. For yeast experiments, coding DNA sequences were
expressed from inducible Gal1/10 promoters.
31 Plasmids-expressing caspase 2,
caspase 3-lacZ, caspase 5, caspase 7
53, caspase 8, CED-3, reverse DRICE,
DCP-1, DRONC, AcP35, AcP35-F, AcP35
D87A-F and SpliP49-F have been
described previously.
11,21,32–34 Other plasmids were generated as follows: the
caspase1codingregionwasampliﬁedusingoligonucleotides1and2frompET21b-
Casp-1-His (purchased from Addgene Cambridge, MA, USA). The product was
cut with BamHI/XbaI and ligated into pGALL-(LEU2)
32 cut with BamHI/XbaI. The
MaviP35 coding region was ampliﬁed with oligonucleotides 3 and 4 from a plasmid
kindly donated by Prof. Chung-Hsiung Wang, cut with BamHI/XhoI and ligated
into pGALL-(HIS3)
32 cut with BamHI/XhoI. MaviP35 was also ampliﬁed with
oligonucleotides 3 and 5 and cloned the same way into pGALL-(HIS3), to
incorporate a carboxyl terminal FLAG tag. Site-directed mutagenesis to generate
MaviP35
D87A was performed using PCR. After excising MaviP35 from pGALL-
(HIS3)-MaviP35andinsertingitintoBluescriptII SKþ via BamHI/XhoI,a PCRwas
conducted using MaviP35-F as a template (oligonucleotides 6 and 7) to amplify
the 30 portion of the gene incorporating a P1 mutation. This product was cut with
Figure 5 MaviP35inhibitsrecombinant caspasesinvitro. Cleavageof ﬂuorogenicsubstrates bypuriﬁedrecombinantcaspases(at theindicatedconcentrations)isplotted
as the change in RFU per minute, in the presence of 1mM of FLAG-tagged MaviP35, AcP35 or truncated CED-9 (a cytosolic protein devoid of caspase inhibitory activity).
The dotted line indicates 10% activity, relative to the substrate cleavage rate in the presence of the control protein
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P1-mutated MaviP35-F gene was then excised with BamHI/XhoI and ligated
into pGALL-(HIS3). For mammalian and insect cell expression, MaviP35-F was
ampliﬁed from pGALL-(HIS3)-MaviP35-F with oligonucleotides 8 and 7, then cut
with BamHI/XhoI, blunted and inserted into pHSP70PLVI
þCAT (chloramphenicol
acetyl transferase)
35 cut with BglII/EcoRI blunted or pEF
36 cut with BamHI/XbaI
blunted. Caspase 3 was ampliﬁed using primers 9 and 10, then digested with NdeI/
XhoI and ligated into NdeI/XhoI cut pET23a. All ampliﬁed fragments were
sequenced to verify the absence of any unintentional mutations. The pAct5eGFP
vector was kindly provided by Samuel Le Fort and David Vaux. The coding
sequencing of DRICE
C211A was ampliﬁed from pGMR-DRICE
C211A (described
below) using primers 11 and 12, cut with BglII and cloned into pACT5eGFP cut with
BamHI to generate pACT5c-DRICE
C211A-eGFP. Restriction analyses and
sequencing were performed to determine the orientation of the insert and to
check the sequence was correct. pGMR-DRICE was made by amplifying DRICE
with primers13 and 14,then cutting theproduct with BglII and XbaI and cloninginto
pGMR.
37pGMR-DRICE
C211Awasconstructedbyamplifyingthe30 portionofDRICE
encoding the active site with a mutagenic forward primer (15) and wild-type reverse
primer(16),digestingtheproductwithNheIandNotIandligatingintopGMR-DRICE
cut with NheIandNotI.TheDNAencodingeGFPwas removedfrompAct5eGFPby
cutting with BamHI and XbaI, blunting using Klenow polymerase and religating to
yield pAct5c. BamHI/XbaI fragments encoding either DIAP1 (obtained by digesting
pGALL-(HIS3)-DIAP1) or MaviP35-FLAG (excised from pGALL-(HIS3)-MaviP35-F)
were ligated into BamHI/XbaI cut pAct5c-eGFP, replacing the eGFP gene.
The sequences of the nucleotides referred to above were as follows:
1: 50-CGGGATCCATGGCCGACAAGGTCCTGAAGGAG-30
2: 50-GCTCTAGATTAATGTCCTGGGAAGAGGTAGAAACATC-30
3: 50-GGGATCCCATATGTGTGTAATTTTTCCAGTAG-30
Figure 6 MaviP35 is cleaved by DRONC but does not inhibit DRONC activity in vitro.( a) Yeast were transformed with the indicated expression plasmids. Suspensions
containing equivalentconcentrationsof each transformant wereserially diluted,and5ml of eachdilutionwerespottedonto inducingandrepressingplates.A totalof 400ng of
FLAG-tagged MaviP35 (b) or AcP35 (c) were incubated with 0, 15, 150 or 1500nM of DRONC or DRICE, then processing was monitored by anti-FLAG immunoblotting. (d)
Drosophila Kc167cells were co-transfected with a plasmid encoding either eGFP or DRICE
C211A-eGFP, together with either an empty vector or plasmid directing expresionof
AcP35-F, MaviP35-FLAG or DIAP1. Transfectants were incubated in media containing or lacking 1mM actinomycin D (ActD) fo 12h. Lysates were subjected to anti-GFP or
anti-FLAGimmunoblotting, or coomassie staining. (e) The structure of the DRICE
C211A–eGFP fusion protein is shown. (f) Cleavageof Ac-TQTD-AFC by puriﬁed recombinant
DRONC is plotted as the change in RFU per minute, in the presence of 1.6mM of FLAG-tagged MaviP35, AcP35 or truncated CED-9
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5: 50-GCCTCGAGTTACTTGTCATCGTCGTCCTTGTAGTCCATATCA
ATGTTTAATATTA TATTGTTG-30
6: 50-CAATTTGATCAACTAGAACGCGACCACAGCACTCAATTCGCT
GGAGGCC-30
7: 50-CTTTATTATTTTTATTTTATTGAGAGGGTGG-30
8: 50-GCGGATCCGCCATGTGTGTAATTTTTCCAGTAG-30
9: 50-GGAATTCCATATGGAGAACACTGAAAACTCAGTGG-30
10: 50-CCCTCGAGGTGATAAAAATAGAGTTCTTTTGTGAGC-30
11: 50-GTCAGATCTCAAAATGGACGCCACTAACAATGGAG-30
12: 50-GTCAGATCTACCCGTCCGGCTGGAGCCAAC-30
13: 50-CGAGATCTCCGCCATGGACGCCACTAACAATGGAGAATCC-30
14: 50-CGTCTAGACTAAACCCGTCCGGCTGGAGCCAACTGC-30
15: 50-CCTCGCTAGCCGGCAAACCCAAGTTGTTCTTCATACAGGCCG
CCCAGGGC-30
16: 50-GCACTAGTGCGGCCGCCTAAACCCGTCCGGCTGGAGCCAAC
TGC-30
Apoptosis assays from insect cells. Sf21 cells were plated at 8 10
5
cells per well in six-well plates in TC-100 insect medium (Invitrogen, Carlsbad, CA,
USA) plus 10% fetal bovine serum (FBS; Atlanta Biologicals, Atlanta, GA, USA),
and allowed to attach overnight at 271C. Transfections were performed using
lipofectin, which was prepared as a 1.5:1 mixture of DOTAP ((N-(1-(2,3-
Dioleoyloxy)propyl)-N,N,N,-trimethylammonium chloride salt; Avanti Polar Lipids,
Alabaster, AL, USA) and DOPE (L-a Phosphatidylethanolamine, dioleoyl; Sigma-
Aldrich,St. Louis,MO, USA). For each well, 2.5mg of theeGFP expression plasmid
pHSP70GFPBsu36I
38 was mixed with 2.5mg of either pHSP70PLVI
þCAT,
pHSP70PLVI
þAcP35 or pHSP70PLVI
þMaviP35F. This DNA was diluted to
100ml with TC-100 lacking FBS and incubated for 5min at room temperature (RT).
Inaseparatetube,6mllipofectinwasdilutedto100ml withTC-100lackingFBSand
incubated for 5min at RT. The mixtures of DNA and lipofectin were then combined
and allowed to incubate for 15min at RT. During this incubation the Sf21 cells were
washedtwicewith1mlofTC-100lackingFBS.Afterthelastwash,800mlofTC-100
lackingFBSwasleft ineachwell andtheDNA/lipofectin mixture(200ml) wasadded
to each well and allowed to incubate at 271C for 4h. The mixture plus the media
were removed and 2ml of TC-100 plus 10% FBS was added to each well. The cells
were heat shocked 24h post transfection at 421C for 30min, to drive expression
fromthehsp70promoter.Thecellsweretheninducedtoundergoapoptosis4hpost
heat shock, by treatment with either UV (by placing the plates on a transilluminator
for 10min) or actinomycin D (Invitrogen; 250ng/ml). To determine cell viability, the
number of GFP-expressing cells was counted in each well both immediately before
and 17h after UV or actinomycin D treatment. Three random ﬁelds of view
per sample were counted per well, and three separate wells were assayed per
treatment.
To assay sensitivity to infection-mediated apoptosis, Sf9 cells (10
6) were plated
in six-well culture dishes for 2h in the TC-100 medium with 10% FBS. After 2h, the
medium was replaced with Grace’s insect unsupplemented medium (Invitrogen).
Cells were transiently transfected with pHSP70PLVI
þCAT, pHSP70PLVI
þAcP35
or pHSP70PLVI
þMaviP35F using 3mg of each plasmid and 6ml of lipofectin.
TransfectionmixtureswerereplacedwithTC-100plus10%FBSafter5hincubation
with cells. Cells were infected at 24h post transfection with vAcP35KO-PG
39 at a
multiplicity of infection of 1 PFU/cell, and then harvested at 48h post infection for
caspase and viability assays. Caspase assays were performed using the substrate
Ac-DEVD-AFC (MP Biomedicals, Solon, OH, USA) as described previously.
40 To
assess viability, three random ﬁelds of view were photographed ( 200
magniﬁcation), and viable cells were counted for each well. Cell viability was
determined by counting the non-apoptotic cells and comparing to the number of
viable cells in a mock-infected control at 0h post infection, which was set at 100%.
DRICE cleavage assays in Kc167 cells. Two million Kc167 cells (kindly
provided by Gary Hime) were transfected with 0.2mg of either pAct5c-eGFP
or pAct5c-DRICE-eGFP plus 1.8mg of either pAct5c, pAct5c-MaviP35-F or pAct5c-
DIAP1, using the Effectene transfection reagent (Qiagen, Doncaster, Victoria,
Australia) according to the manufacturer’s instructions. After 24h transfection, the
cells were incubated in media containing 0 or 1mM of actinomycin D for 12h. Cells
were lysed in mammalian lysis buffer (50mM Tris pH 7.5, 375mM NaCl, 1mM
ethylenediamine tetra-acetic acid, 1% Triton X-100) containing protease inhibitors
(protease inhibitor cocktail set 1; Calbiochem, Darmstadt, Germany) and subjected
to12%SDS-PAGEandeitherCoomassiestainedorimmunoblottedusinganti-GFP
(RocheAppliedScienceno.11814460001;CastleHill,NewSouthWales,Australia)
or anti-FLAGM2 (Sigma no. F3165) and anti-mouse IgG-HRP (Sigma no. A9044).
Figure7 MaviP35isanefﬁcientinhibitorofexecutionercaspasesinvitro.PuriﬁedFLAG-taggedMaviP35andAcP35weretestedinvitrofortheirabilitytoinhibitcleavage
ofﬂuorogenicpeptidesubstratesbyhumancaspases3,8and9andDrosophilaDRICEandDRONC.Hydrolysisoftheindicatedsubstrateswasmonitoredinthepresenceofa
range of inhibitor concentrations. Graphs show the impact of various concentrations of MaviP35 on DRONC (a) and DRICE (b) activity. (c) Inhibition constants (Ki) were
calculated for selected caspases using a competitive model, as described in the Materials and Methods
Characterization of MaviP35
IL Brand et al
8
Cell Death and DiseaseMammalian apoptosis assays. SV-40 transformed mouse embryonic
ﬁbroblasts (MEFs) were co-transfected with 1mg of CMV-lacZ and either 3mgo f
pEF, AcP35-pEF or MaviP35-pEF using FuGENE HD transfection reagent (Roche;
Basel, Switzerland). LN18 glioblastoma cells (ATCC; Manassas, VA, USA) were
co-transfected with 1mg of CMV-lacZ and either 2mg of pEF, AcP35-pEF or
MaviP35-pEF using Lipofectamine (Invitrogen). Transfections were performed
according to the manufacturers’ instructions. Twenty-four hours after transfection,
the medium was removed and the cells were incubated with fresh unsupplemented
media or media containing cisplatin (Mayne Pharma, Mulgrave, Victoria, Australia)
orSuperkiller (crosslinked) TRAIL (Alexis Biochemicals,Lausen,Switzerland).After
24h, the cells were stained with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside
andthebluecellswerescoredforviableversusapoptoticmorphology,aspreviously
published.
36
Yeast transformation and death assays. Saccharomyces cerevisiae
yeast strain W303a was transformed
31 and analyzed in survival assays
21 as
described previously.
31 Caspase 1 was expressed using the pGALL-(LEU2)-Casp1
vector described above.
Proteinassaysfromyeast. Yeast transformants weregrown andtransgene
expression induced as described previously.
11 The lysates were subjected to
SDS-PAGE and the gels were then stained with Coomassie brilliant blue (Sigma)
to visualize protein loading and immunoblotted as described previously.
11 The
membranes were probed with an antibody recognizing the FLAG tag (clone M2;
Sigma) and anti-mouse-HRP (Sigma). To measure the caspase activity via
ﬂuorescence analysis, the yeast were treated as follows: An overnight culture was
pelleted, washed twice with 1ml of TE (Tris HCl 10mM pH 8, EDTA 1mM) and
induced for 6.5h in complete media containing 2% galactose. After pelleting the
yeastculture,theyeastwasweighedandglassbeadswereadded.Tolysethecells,
5mlofCelLyticYreagent(Sigma)with10mMDTTwasaddedper1gofyeastcells.
After gently shaking the cells for 30min at RT, the debris was removed by
centrifugation at 16100 g for 10min at 41C. The protein concentration of the
supernatant was measured using the Bicinchoninic acid protein assay kit (Sigma).
In ﬂuorescence assays, lysate (0.5mg/ml) was mixed with Ac-DEVD-AFC (100mM)
in DRICE activity buffer (50mM HEPES pH7.5, 10% sucrose, 0.1% CHAPS, 5mM
DTT, 100mM NaCl, 1mM EDTA), and the ﬂuorescence (excitation 410nm,
emission 500nm) was measured every 30s for 1h. The slope of each curve was
calculated using Graphpad Prism 5.0 (La Jolla, CA, USA). The slope of each curve
determines the concentration of free AFC per minute, which provides a measure of
caspase activity.
Protein puriﬁcation from yeast. Transformants were grown in 5ml
glucose-containing selective medium to stationary phase, then expanded by addition
of 195mlglucose-containing selectivemedium.Afterexpandingthe cellsfor 16–18h,
the pelleted yeast were washed once with 100ml TE and resuspended in 1l of
galactose-containing complete media for 6.5h induction. Cells were harvested at
12100 g,4 1C for 15min then glass beads were added after weighing the pellets.
To lyse the cells CelLyticY reagent (Sigma) was used as described above. The
supernatant was incubated for 30min at 41Cw i t h2 0 0ml Anti-FLAG M2 afﬁnity gel
(Sigma), which had been previously washed three times with 12  resin volume
washing buffer (Tris HCl 50mM pH 7.4, 150mM NaCl). Incubated beads were
pelleted 5min at 3750g, RT then washed with 32resinvolumes ofwashing buffer for
10min at 41C. Five elution fractions were collected each using one resin volume of
elution buffer (1mM HEPES pH 7.0, 0.1% PEG, 0.001% CHAPS, 0.1mM DTT,
200ng/mlFLAGpeptide(Sigma)).Foreachelutionstepthebeadswereincubatedfor
2minat41Cwithagitation,andsupernatantwascollectedafterapelletingfor1minat
16100g, 41C. After subsequent SDS-PAGE analysis and Coomassie brilliant blue
(Sigma) staining, the fractions containing pure FLAG-tagged proteins were pooled,
andproteinconcentrationwasdeterminedusingtheBio-RadProteinAssay(Bio-Rad,
Gladesville, New South Wales, Australia).
Recombinant caspases. Caspases 1, 2, 6, 7, 8, 9 and 10 were purchased
from Enzo Life Sciences (Farmingdale, NY, USA). BL21-(DE3)-pLysS (Merck,
Darmstadt, Germany) bacteria were transformed with caspase 3-pET23a
(described above) or the following previously published plasmids: DCP-1-
pET23a,
32 DRICE-pET23a,
32 CED-3-pET23a,
34 DRONC-pET23a.
11 Caspase 3,
DCP-1, DRICE and CED-3 were puriﬁed as described previously.
34 DRONC
puriﬁcation was carried out as follows: A transformant colony was inoculated into
1.5ml 2YT-amp/chlor (16g/l tryptone, 10g/l yeast extract, 5g/l NaCl, 100mg/ml
ampicillinand35mg/mlchloramphenicol) andgrown overnightat 371C. A volumeof
1ml of this culture was expanded into 50ml of pre-warmed 2YT-amp/chlor and
grown at 371C for 2h, 200r.p.m. A total of 10ml of this was mixed with 190ml of
pre-warmed 2YT amp/chlor in a 2-l bafﬂed ﬂask and shaken at 371, 200r.p.m.
until OD600 reached 0.6–0.8. IPTG was added to a ﬁnal concentration of 1mM and
theculturewas shakenat 201Cfor 18h,then pelletedfor 10minat 3000g,41Cand
then frozen at  801C. The pellet was thawed then resuspended in a 10-ml Bug
Buster Mastermix (Merck) by pipetting, then incubated for 20min at RT. Insoluble
cell debris was removed by centrifugation at 16100 g for 20min at 41C. Half a
milliliter of NiNTA resin (Qiagen) was washed twice in phosphate buffer (50mM
NaHPO4,300mMNaCl),thenincubatedwiththeinducedbacteriallysatefor 30min
at 41C, gently mixing. The beads were washed twice with phosphate buffer
containing 5mM imidazole, then the caspase was eluted with phosphate buffer
containing 250mM imidazole.
In vitro quantitation of caspase inhibition. Caspases 1, 2, 3, 6, 7, 8, 9,
10, DRICE, DCP-1 and CED-3 were pre-activated for 10min at 371C in universal
caspase citrate buffer (10mM HEPES pH 7.0, 10% sucrose, 0.1% CHAPS, 10mM
DTT, 100mM NaCl, 1mM EDTA, 0.65M Na-Citrate). After the activation step, the
caspase was incubated either with buffer alone, F-CED-9
1–251, AcP35-F or with
MaviP35-F for 1h at 371C. The appropriate ﬂuorescent substrate was then added
(100mM):Ac-WEHD-AFCforcaspase1;Ac-VDVAD-AFCforcaspase2;Ac-DEVD-
AFC for caspases 3, 7, DRICE, DCP-1 and CED-3; Ac-VEID-AFC for caspase 6;
Ac-LEHD-AFC for caspases 8, 9 and 10 and Ac-TQTD-AFC for DRONC (Enzo Life
Sciences). Fluorescence (excitation 410nm, emission 500nm) was measured
every minute for 2h. The maximal slope of each curve was calculated using Prism
5.0 and graphed.
Determination of inhibition constants. Caspaseswere pre-activated for
10min at 371C in the following buffers: caspase 3: 100mM HEPES pH 7.0, 10%
PEG, 0.1% CHAPS, 10mM DTT; DRICE: 50mM HEPES pH 7.5, 10% sucrose,
0.1% CHAPS, 5mM DTT, 100mM NaCl, 1mM EDTA; caspases 8 and 9: 10mM
HEPES pH 7.0, 10% sucrose, 0.1% CHAPS, 10mM DTT, 100mM NaCl, 0.1mM
EDTA, 0.65M Na-Citrate; DRONC: 50mM Tris pH 7.4, 100mM NaCl, 0.65M
Na-Citrate. Subsequently, the caspase was incubated with either AcP35-F or
MaviP35-F in the appropriate activity buffer for 1h at 371C. Substrates were added
atconcentrationsrangingfrom0.001to1000mM.Substratesusedwere:Ac-DEVD-
AFC for caspase 3 and DRICE; Ac-LEHD-AFC for caspases 8 and 9 and Ac-VEID-
AFC for DRONC (Enzo Life Sciences). Fluorescence (excitation 410nm, emission
500nm) was measured every minute for 2h. The slope of each curve was
calculated using Prism 5.0. Inhibition constants were calculated by non-linear
regression using Prism 5.0 software, using a competitive inhibition model
as described by these equations: Km
Obs¼Km (1þ[I]/Ki) and Y¼Vmax X/
(Km
ObsþX), where [I] is the inhibitor concentration (mM); Ki is the inhibition constant
(mM),Vmaxisthemaximumenzymevelocity(relativeﬂuorescenceunits(RFU)/min),
Km is the Michaelis–Menten constant(mM), X is the concentrationof substrate(mM)
and Y is the change in ﬂuorescence (RFU/min).
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